Loading headlines…

Collected headline brief
Parabilis Medicines Inc., a clinical-stage cancer drug developer, raised nearly $745 million in an upsized US initial public offering that priced above its marketed range, and a private placement.
There is more to this story
Complete reading on newsGlobal
Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →